742 related articles for article (PubMed ID: 27179830)
1. The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy.
Mallick A; Gandhi PU; Gaggin HK; Ibrahim N; Januzzi JL
JACC Heart Fail; 2016 Sep; 4(9):749-55. PubMed ID: 27179830
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
3. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
4. Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients.
Stienen S; Salah K; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Tijssen JP; Pinto YM; Kok WE
JACC Heart Fail; 2016 Sep; 4(9):736-45. PubMed ID: 27395353
[TBL] [Abstract][Full Text] [Related]
5. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Bhardwaj A; Rehman SU; Mohammed AA; Gaggin HK; Barajas L; Barajas J; Moore SA; Sullivan D; Januzzi JL
Am Heart J; 2012 Nov; 164(5):793-799.e1. PubMed ID: 23137512
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
Sanders-van Wijk S; Muzzarelli S; Neuhaus M; Kiencke S; Maeder M; Estlinbaum W; Tobler D; Mayer K; Erne P; Pfisterer ME; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Aug; 15(8):910-8. PubMed ID: 23666681
[TBL] [Abstract][Full Text] [Related]
7. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study.
Núñez J; Llàcer P; Bertomeu-González V; Bosch MJ; Merlos P; García-Blas S; Montagud V; Bodí V; Bertomeu-Martínez V; Pedrosa V; Mendizábal A; Cordero A; Gallego J; Palau P; Miñana G; Santas E; Morell S; Llàcer A; Chorro FJ; Sanchis J; Fácila L;
JACC Heart Fail; 2016 Nov; 4(11):833-843. PubMed ID: 27522630
[TBL] [Abstract][Full Text] [Related]
8. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
[TBL] [Abstract][Full Text] [Related]
9. Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
Ibrahim NE; Gaggin HK; Rabideau DJ; Gandhi PU; Mallick A; Januzzi JL
J Card Fail; 2017 Feb; 23(2):121-130. PubMed ID: 27469482
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
11. Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF.
Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano GMC; Dahlström U; Lund LH
JACC Heart Fail; 2018 Mar; 6(3):246-256. PubMed ID: 29428439
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
[TBL] [Abstract][Full Text] [Related]
13. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
[TBL] [Abstract][Full Text] [Related]
14. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
[TBL] [Abstract][Full Text] [Related]
15. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction.
Daubert MA; Yow E; Barnhart HX; Piña IL; Ahmad T; Leifer E; Cooper L; Desvigne-Nickens P; Fiuzat M; Adams K; Ezekowitz J; Whellan DJ; Januzzi JL; O'Connor CM; Felker GM
J Am Heart Assoc; 2021 May; 10(10):e019712. PubMed ID: 33955231
[TBL] [Abstract][Full Text] [Related]
16. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
17. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.
Butler J; Yang M; Manzi MA; Hess GP; Patel MJ; Rhodes T; Givertz MM
J Am Coll Cardiol; 2019 Mar; 73(8):935-944. PubMed ID: 30819362
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe.
Fröhlich H; Rosenfeld N; Täger T; Goode K; Kazmi S; Hole T; Katus HA; Atar D; Cleland JGF; Agewall S; Clark AL; Frankenstein L; Grundtvig M
Heart; 2019 Aug; 105(16):1252-1259. PubMed ID: 30792238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
